Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

La Jolla, USA
11099 N. Torrey Pines Road
Suite 100
La Jolla, CA, 92037
USA

People

CSO
CMO
President and CEO
Chairman

Funding

TOTAL $16.8M
FUNDING TOTAL $16.8M
Partial Close, 3/2008
$11.2M
Series B, 8/2013
Jacobs Investment Company
$5.6M

Tags

DermTech International

DermTech develops and commercializes qPCR assays for skin samples collected non-invasively using adhesive tape biopsy methods. The Company’s assays can analyze multiple gene targets to assess their level of RNA expression. The Company anticipates providing these assays through a CLIA certified laboratory located in San Diego.

The Company will initially offer an assay for pigmented skin lesions sampled using an adhesive tape collection method. The Company has identified gene targets differentially expressed in melanoma samples (British Journal of Dermatology, April 2011). This assay can assess RNA expression consistent with melanoma with very high sensitivity (>95%) and specificity (>70%).

Recent Milestones

Videos

Screenshots

DermTech International screenshot
Above: Homepage
Uploaded: 8/19/13

Sources

  1. SEC (sec.gov) [edit]
  2. DermTech raises $5.6m in first close of Series B financing (finsmes.com) [edit]
Edit This Page
Last Edited 12/14/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy